Literature DB >> 15334545

MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).

Therese Nilsson1, Lars Nilsson, Stig Lenhoff, Lars Rylander, Ingbritt Astrand-Grundström, Bodil Strömbeck, Mattias Höglund, Ingemar Turesson, Jan Westin, Felix Mitelman, Sten E W Jacobsen, Bertil Johansson.   

Abstract

Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are characterized cytogenetically by 14q32 rearrangements, -13/13q-, and various trisomies. Occasionally, karyotypic patterns characteristic of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) occur in MM, often signifying therapy-related (t)-MDS/t-AML. Comparison of cytogenetic features in all published MMs (n = 993) and t-MDS/t-AML post-MM (n = 117) revealed significant differences in complexity and ploidy levels and in most genomic changes. Thus, these features often can be used to distinguish between MM and t-MDS/t-AML. Rarely, myeloid-associated aberrations are detected in MM without any signs of MDS/AML. To characterize such abnormalities in MM/MGUS, we ascertained all 122 MM and 26 MGUS/smoldering MM (SMM) cases analyzed in our department. Sixty-six (54%) MMs and 8 (31%) MGUS/SMMs were karyotypically abnormal, of which 6 (9%) MMs and 3 (38%) MGUS/SMMs displayed myeloid abnormalities, that is, +8 (1 case) and 20q- (8 cases) as the sole anomalies, without any evidence of MDS/AML. One patient developed AML, whereas no MDS/AML occurred in the remaining 8 patients. In one MGUS with del(20q), fluorescence in situ hybridization analyses revealed its presence in CD34+CD38- (hematopoietic stem cells), CD34+CD38+ (progenitors), CD19+ (B cells), and CD15+ (myeloid cells). The present data indicate that 20q- occurs in 10% of karyotypically abnormal MM/MGUS cases and that it might arise at a multipotent progenitor/stem cell level. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15334545     DOI: 10.1002/gcc.20078

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Mosaic chromosome 20q deletions are more frequent in the aging population.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Nathaniel Rothman; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  Blood Adv       Date:  2017-02-13

Review 2.  De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.

Authors:  Giuseppe Leone; Emiliano Fabiani; Maria Teresa Voso
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

3.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

4.  In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

Authors:  Carina S Debes Marun; Andrew R Belch; Linda M Pilarski
Journal:  Am J Hematol       Date:  2012-04-12       Impact factor: 10.047

5.  The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.

Authors:  Stéphanie Trudel; Hussein Ghamlouch; Julie Dremaux; Caroline Delette; Véronique Harrivel; Jean-Pierre Marolleau; Brigitte Gubler
Journal:  Front Immunol       Date:  2016-12-27       Impact factor: 7.561

6.  Evidence of two different molecular mechanisms as a consequence of an isolated 20q- abnormality in a case of multiple myeloma accompanied with myelodysplastic syndrome.

Authors:  Lubomir Mitev
Journal:  Leuk Res Rep       Date:  2021-10-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.